Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1

Cell Reports

Volumn 7, Issue 4, 2014, Pages 999-1008

  Pirazzoli, Valentina ^a   Nebhan, Caroline ^b   Song, Xiaoling ^a   Wurtz, Anna ^a   Walther, Zenta ^c   Cai, Guoping ^c   Zhao, Zhongming ^b   Jia, Peilin ^b   de Stanchina, Elisa ^d   Shapiro, Erik M ^e   Gale, Molly ^c   Yin, Ruonan ^c   Horn, Leora ^f   Carbone, David P ^g   Stephens, Philip J ^h   Miller, Vincent ^h   Gettinger, Scott ^a,c   Pao, William ^b,f   Politi, Katerina ^a,c  

^a YALE CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e St John Hospital and Medical Center   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CETUXIMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; THYROID TRANSCRIPTION FACTOR 1; VASCULOTROPIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PLACEBO; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOCLONAL ANTIBODY; MULTIPROTEIN COMPLEX; QUINAZOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC ENGINEERING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; XENOGRAFT; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DRUG TARGETING; EGFR GENE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENOMICS; HUMAN TISSUE; MTORC1 GENE; MUTATIONAL ANALYSIS; NF2 GENE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TSC1 GENE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CETUXIMAB; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; MUTATION; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901275269     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.04.014     Document Type: Article

References (20)

1. Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K., Somwar R., Wang L., Amato K.R., Arcila M., Sos M.L., et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 2011, 3:90ra59.
2. Curto M., Cole B.K., Lallemand D., Liu C.H., McClatchey A.I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 2007, 177:893-903.
3. Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S.R., He J., Schnall-Levin M., White J., Sanford E.M., An P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
4. James M.F., Han S., Polizzano C., Plotkin S.R., Manning B.D., Stemmer-Rachamimov A.O., Gusella J.F., Ramesh V. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell. Biol. 2009, 29:4250-4261.
5. Janjigian Y.Y., Smit E.F., Horn L., Groen H.J.M., Camidge D.R., Gettinger S., Fu Y., Denis L.J., Miller V., Pao W. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. Ann. Oncol. 2012, 23:ix400-ix446.
6. Jeselsohn R., Yelensky R., Buchwalter G., Frampton G.M., Meric-Bernstam F., Gonzalez-Angulo A.M., Ferrer-Lozano J., Perez-Fidalgo J.A., Cristofanilli M., Gómez H., et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor positive breast cancer. Clin. Cancer Res. 2014, 20:1757-1767.
7. Lamszus K., Lachenmayer L., Heinemann U., Kluwe L., Finckh U., Höppner W., Stavrou D., Fillbrandt R., Westphal M. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int. J. Cancer 2001, 91:803-808.
8. Laplante M., Sabatini D.M. mTOR signaling. Cold Spring Harb. Perspect. Biol. 2012, 4:4.
9. Li D., Shimamura T., Ji H., Chen L., Haringsma H.J., McNamara K., Liang M.C., Perera S.A., Zaghlul S., Borgman C.L., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12:81-93.
10. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., Padera R.F., Shapiro G.I., Baum A., Himmelsbach F., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
11. López-Lago M.A., Okada T., Murillo M.M., Socci N., Giancotti F.G. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 2009, 29:4235-4249.
12. Ohashi K., Maruvka Y.E., Michor F., Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 2013, 31:1070-1080.
13. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
14. Politi K., Fan P.D., Shen R., Zakowski M., Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis. Model. Mech. 2010, 3:111-119.
15. Regales L., Balak M.N., Gong Y., Politi K., Sawai A., Le C., Koutcher J.A., Solit D.B., Rosen N., Zakowski M.F., Pao W. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2007, 2:e810.
16. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Ouerfelli O., Mellinghoff I.K., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 2009, 119:3000-3010.
17. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
18. Tichelaar J.W., Lu W., Whitsett J.A. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J. Biol. Chem. 2000, 275:11858-11864.
19. Walter A.O., Sjin R.T., Haringsma H.J., Ohashi K., Sun J., Lee K., Dubrovskiy A., Labenski M., Zhu Z., Wang Z., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013, 3:1404-1415.
20. Zemmoura I., Vourc'h P., Paubel A., Parfait B., Cohen J., Bilan F., Kitzis A., Rousselot C., Parker F., François P., Andres C.R. A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma. Neuro-oncol. 2014, 16:250-255.